1. Scrip
  2. >>Business
  3. >>Strategy

Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

 
• By Joseph Haas

On pace to file selective JAK1 inhibitor filgotinib for US approval in RA by year’s end, Gilead says the drug’s safety profile may allow for a labeling advantage compared with other drugs in the class.

Close Up Of Senior Man At Home Suffering With Arthritis - Image
Rheumatoid arthritis may be the first of several indications for filgotinib

As it nears the filing of a new drug application in the US for filgotinib in rheumatoid arthritis, Gilead Sciences Inc. is telling investors that it believes the selective JAK1 inhibitor may enjoy a better safety profile than other drugs in its class.

Gilead stepped in to partner on filgotinib with Galapagos NV back in 2015, making a $725m up-front commitment, after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By Vibha Ravi

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.